Who Owns Kenvue?

Who owns Kenvue?
Kenvue is a wholly owned subsidiary of Kimberly-Clark listed on the New York Stock Exchange under the ticker KVUE. No single shareholder holds a controlling stake. Institutional investors hold the majority of shares. Johnson & Johnson fully divested its Kenvue shares in August 2023 through an exchange offer. Upon completion of the Kimberly-Clark acquisition, expected in Q4 2026, Kenvue will become a wholly owned subsidiary of Kimberly-Clark Corporation.

Is Kenvue being acquired?
Yes. On November 2, 2025, Kimberly-Clark announced a definitive merger agreement to acquire Kenvue for approximately $48.7 billion in cash and stock. Shareholders of both companies approved the transaction on January 29, 2026. The HSR waiting period expired on February 4, 2026. The transaction is closed on November 2, 2026.

What is Kenvue's revenue?
Kenvue reported FY2025 net sales of $15.1 billion, down 2.1% from $15.5 billion in FY2024. FY2025 net income was $1.47 billion, with diluted EPS of $0.76 and adjusted diluted EPS of $1.08. In Q1 2026, net sales grew 3.2% and organic sales grew 1.2%. In Q2 2026, the company reported its third consecutive quarter of growth across all segments and regions.

Who is the CEO of Kenvue?
Kirk Perry serves as CEO of Kenvue. He was named interim CEO in early 2025 following the termination of previous CEO Thibaut Mongon, and was named permanent CEO in November 2025. Under Perry's leadership, Kenvue has delivered three consecutive quarters of net and organic sales growth and is executing a 2026 Restructuring Initiative targeting $250 million in pre-tax charges for supply chain optimization.

Is Kenvue still publicly traded?
Yes, Kenvue continues to trade on the New York Stock Exchange under the ticker KVUE as of August 2026. Upon completion of the Kimberly-Clark acquisition, expected in Q4 2026, Kenvue shares will be delisted as the company becomes a wholly owned subsidiary of Kimberly-Clark.

When was Kenvue founded?
Kenvue was spun off from Johnson & Johnson in May 2023 via an IPO that raised $3.8 billion. J&J completed the full separation in August 2023 through an exchange offer. The company was created to operate independently as a focused consumer health company, allowing J&J to concentrate on its pharmaceutical and medical device businesses.

What brands does Kenvue own?
Kenvue owns Tylenol, Listerine, Band-Aid, Neutrogena, Aveeno, Zyrtec, Johnson's, Motrin, Benadryl, Sudafed, Pepcid, Imodium, Nicorette, Visine, and Calpol. These brands hold number-one or number-two market positions in their respective categories.

Where is Kenvue headquartered?
Kenvue is headquartered in Summit, New Jersey, USA. The company relocated from Skillman, New Jersey, where it was initially based following the spin-off from Johnson & Johnson. Kenvue is incorporated in Delaware and maintains manufacturing facilities, research and development centers, and distribution networks across the United States, Europe, Asia, and Latin America.

What is the Kimberly-Clark Kenvue merger?
The Kimberly-Clark Kenvue merger is a pending acquisition announced on November 2, 2025, under which Kimberly-Clark will acquire all outstanding Kenvue shares in a cash and stock transaction valued at approximately $48.7 billion enterprise value. The combined company would generate approximately $32 billion in annual revenue and $7 billion in adjusted EBITDA. Kimberly-Clark identified $1.9 billion in cost synergies and $500 million in revenue synergies. The transaction is closed on November 2, 2026.